To overcome these, combination therapies comprising DNMT inhibitors, chemotherapeutic agents, and, more recently, immune checkpoint inhibitors might constitute a valid option for BC patients, as demonstrated by the currently ongoing clinical trials. This evidence concerns the gene DNMT1 and breast cancer.